1 February 2016 - The FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier.

For more details, go to: http://investor.eagleus.com/press-release/fda-grants-fast-track-designation-ryanodex-treatment-exertional-heat-stroke-fast-track